In parallel, fixed multipeptide vaccines like IMA950, which targets a fixed set of glioblastoma-associated antigens (e.g., BCA, CSPG4), are also being explored in combination with checkpoint inhibitors [42,43]. The gene discussed is BLNK; the disease is glioblastoma.